Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Non-invasive Vagal Nerve Stimulation as Novel Treatment to Improve Functional Outcomes in Veterans With Alcohol Use Disorder

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
San Diego (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
80 fő, tervezett
Kezdés
2025. jan. 1.
Várható befejezés
2029. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Cervical transcutaneous vagus nerve stimulation (active comparator)
  • Cervical transcutaneous vagus nerve stimulation (sham comparator)
A regiszteradat frissítve
2026. március 23.

Ki vehet részt

Életkor
21 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Veterans between 21 and 65 years, any race or ethnicity
  • Meet current DSM-5 diagnosis of moderate or severe AUD (Structured Clinical Interview for DMS-5 (SCID) interview) with at least one functional disability due to alcohol use, current alcohol craving, and current heavy drinking (>= 5 drinks (men) / >= 4 drinks (women) on the same occasion, on 5 or more days in the past month) as defined by the Substance Abuse and Mental Health Services Administration (SAMHSA), and mild to moderate withdrawal symptoms during abstinence
  • Able to forgo consumption of alcohol for 12-24 hours without any serious discomfort or complications
  • Capable of complying with study schedule, procedures, and speaks English
  • Able to provide voluntary written informed consent prior to initiation of visit 1
  • Able and willing to self-administer nVNS/sham stimulation as instructed for the duration of the study, and willing to commit to the return visit at the end of the study

Ki nem vehet részt

  • Evidence of a maladaptive pattern of substance use or abuse other than alcohol one month prior to screening visit
  • Pharmacotherapy for AUD: >= 2 weeks stability is required to ensure a steady state of medication effects prior to nVNS administration
  • Currently taking opioids or benzodiazepines
  • Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar) score >10 on the day of the scan (symptoms judged to be due to co-existing anxiety or headache disorders will not be counted toward the total)
  • Recent history past 6 months) of severe complications due to alcohol withdrawal (alcohol withdrawal seizures, hallucinations/illusions, delirium tremens)
  • Uncontrolled severe psychiatric disorder with psychotic symptoms or cognitive impairment. We will not exclude for PTSD
  • History of neurological disorder that might be associated with cognitive dysfunction
  • History of head trauma involving loss of consciousness >24 hours
  • Clinically significant uncontrolled/unstable medical illness or clinically significant surgery within 1 month of the screening visit
  • MRI-related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body, aortic/aneurysm clips, heart-valve replacement, copper intrauterine device, shunt (ventricular or spinal), neuro/bio-stimulators, (for females) pregnant or nursing. Any implants will be reviewed for safety
  • Vagus nerve stimulation related criteria: active implantable medical device, metallic device implanted at or near the neck, carotid atherosclerosis (narrowing of arteries), cervical vagotomy, clinically significant hypertension, hypotension, bradycardia, or tachycardia, cardiac disease and atherosclerotic cardiovascular disease (severe carotid artery disease (e.g., history of transient ischemic attack (TIA) or stroke), congestive heart failure, severe coronary artery disease or recent myocardial infarction (within 5 years))
  • Currently or recently (within last 90 days) enrolled in abstinence-based treatment program
  • At risk for suicide requiring urgent higher-level care or homicide (based on the Columbia-Suicide Severity Rating Scale and follow-up clinical interview)
  • In case it is determined by the investigator during the course of the study, that a subject needs a higher level or care, study participation will be discontinued, and the subject will be excluded from the study

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 21 és 65 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • VA San Diego Healthcare System, San Diego, CASan Diego, Egyesült ÁllamokContact: Ruth Klaming, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Alcohol use disorder (AUD) is a major health concern amongst Veterans as it causes functional impairments and decreased quality of life. Current AUD treatments show limited effectiveness in reducing withdrawal-related psychological and physical distress, which drives the urge to drink to relieve these symptoms. The investigators propose the vagus nerve, which is the primary nerve of the "rest and digest" branch of the autonomic nervous system via its bidirectional connections between the brain and the body, as a novel treatment target for AUD. The goal of this study is to assess treatment efficacy and mechanism of action. Noninvasive neuromodulation technologies offer the possibility for innovative, low risk treatments to support the rehabilitation and community reintegration of Veterans with AUD.

A vizsgálat 2 csoportja

  • Active cervical transcutaneous vagus nerve stimulationMár használt kezelés, összehasonlításként

    Participants will be assigned to active transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.

    Kezelés: Cervical transcutaneous vagus nerve stimulation (active comparator)

  • Sham cervical transcutaneous vagus nerve stimulationPlacebo, összehasonlításként

    Participants will be assigned to sham transcutaneous vagus nerve stimulation, received once during each of the study visits and self-administered twice a day for a week.

    Kezelés: Cervical transcutaneous vagus nerve stimulation (sham comparator)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Kérdések a feltételekről
Forrás: NCT06399653: ki vehet részt
A regiszteradat frissítve
2026. március 23.